Life Expectancy in Long-Term Survivors Transplanted for Myelofibrosis: A Registry Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Background:myelofibrosis is a rare hematological malignancy which can be cured by hematopoietic stem cell transplant (HSCT) and many studies are showing that 3 to 5-year survival after HSCT is between 45 to 70% in relative standard condition (chronic phase disease, HLA matched donor). Relapse and transplant-related mortality are more frequent the first 2 years post HSCT. To optimize the long-term management of these patients, we raised the question of long-term outcome in patients surviving in remission at least 2 years after HSCT. Furthermore, that's a recurrent question from the patient to know if his life expectancy can reach the general population one many years after transplant.